| Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre … TY Seiwert, B Burtness, R Mehra, J Weiss, R Berger, JP Eder, K Heath, ... The lancet oncology 17 (7), 956-965, 2016 | 1810 | 2016 |
| Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE … LQM Chow, R Haddad, S Gupta, A Mahipal, R Mehra, M Tahara, R Berger, ... Journal of Clinical Oncology 34 (32), 3838-3845, 2016 | 900 | 2016 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 786 | 2020 |
| Efficacy of Selpercatinib in RET-Altered Thyroid Cancers LJ Wirth, E Sherman, B Robinson, B Solomon, H Kang, J Lorch, F Worden, ... New England Journal of Medicine 383 (9), 825-835, 2020 | 733 | 2020 |
| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542-1549, 2017 | 703 | 2017 |
| Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer 119 (2), 153-159, 2018 | 468 | 2018 |
| Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration A Drilon, JW Clark, J Weiss, SHI Ou, DR Camidge, BJ Solomon, ... Nature medicine 26 (1), 47-51, 2020 | 377 | 2020 |
| Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline SA Koyfman, N Ismaila, D Crook, A D'Cruz, CP Rodriguez, DJ Sher, ... Journal of Clinical Oncology 37 (20), 1753-1774, 2019 | 329 | 2019 |
| Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer BS Chera, S Kumar, C Shen, R Amdur, R Dagan, R Green, E Goldman, ... Journal of Clinical Oncology 38 (10), 1050-1058, 2020 | 317 | 2020 |
| Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C R Yaeger, J Weiss, MS Pelster, AI Spira, M Barve, SHI Ou, TA Leal, ... New England Journal of Medicine 388 (1), 44-54, 2023 | 302 | 2023 |
| Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open … V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ... The Lancet Oncology 23 (10), 1261-1273, 2022 | 288 | 2022 |
| Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer BS Chera, S Kumar, BT Beaty, D Marron, S Jefferys, R Green, ... Clinical Cancer Research 25 (15), 4682-4690, 2019 | 275 | 2019 |
| Phase II trial of de-intensified chemoradiotherapy for human papillomavirus–associated oropharyngeal squamous cell carcinoma BS Chera, RJ Amdur, R Green, C Shen, G Gupta, X Tan, M Knowles, ... Journal of Clinical Oncology 37 (29), 2661-2669, 2019 | 192 | 2019 |
| Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma BS Chera, RJ Amdur, J Tepper, B Qaqish, R Green, SL Aumer, N Hayes, ... International Journal of Radiation Oncology* Biology* Physics 93 (5), 976-985, 2015 | 192 | 2015 |
| Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). NA Rizvi, JR Brahmer, SHI Ou, NH Segal, S Khleif, WJ Hwu, M Gutierrez, ... Journal of clinical oncology 33 (15_suppl), 8032-8032, 2015 | 187 | 2015 |
| Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial JM Weiss, T Csoszi, M Maglakelidze, RJ Hoyer, JT Beck, MD Gomez, ... Annals of Oncology 30 (10), 1613-1621, 2019 | 171 | 2019 |
| A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. TY Seiwert, B Burtness, J Weiss, I Gluck, JP Eder, SI Pai, M Dolled-Filhart, ... Journal of Clinical Oncology 32 (15_suppl), 6011-6011, 2014 | 166 | 2014 |
| Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinoma BS Chera, RJ Amdur, JE Tepper, X Tan, J Weiss, JE Grilley‐Olson, ... Cancer 124 (11), 2347-2354, 2018 | 147 | 2018 |
| Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). AE Drilon, DR Camidge, SHI Ou, JW Clark, MA Socinski, J Weiss, ... Journal of Clinical Oncology 34 (15_suppl), 108-108, 2016 | 147 | 2016 |
| Treatment of older patients with head and neck cancer: a review NA VanderWalde, M Fleming, J Weiss, BS Chera The oncologist 18 (5), 568-578, 2013 | 143 | 2013 |
